Tredje AP fonden Grows Stock Holdings in Zimmer Biomet Holdings, Inc. $ZBH

Tredje AP fonden increased its position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 44.8% in the 3rd quarter, HoldingsChannel reports. The institutional investor owned 23,531 shares of the medical equipment provider’s stock after buying an additional 7,278 shares during the quarter. Tredje AP fonden’s holdings in Zimmer Biomet were worth $2,318,000 at the end of the most recent reporting period.

Other institutional investors have also bought and sold shares of the company. Legacy Wealth Asset Management LLC lifted its position in shares of Zimmer Biomet by 2.3% in the third quarter. Legacy Wealth Asset Management LLC now owns 4,670 shares of the medical equipment provider’s stock valued at $460,000 after acquiring an additional 106 shares in the last quarter. Global Retirement Partners LLC grew its position in shares of Zimmer Biomet by 7.0% during the third quarter. Global Retirement Partners LLC now owns 1,686 shares of the medical equipment provider’s stock worth $166,000 after purchasing an additional 111 shares in the last quarter. Cullen Frost Bankers Inc. raised its stake in Zimmer Biomet by 66.7% during the 3rd quarter. Cullen Frost Bankers Inc. now owns 290 shares of the medical equipment provider’s stock valued at $29,000 after purchasing an additional 116 shares during the period. Generali Asset Management SPA SGR lifted its holdings in Zimmer Biomet by 0.9% in the 3rd quarter. Generali Asset Management SPA SGR now owns 14,232 shares of the medical equipment provider’s stock worth $1,402,000 after purchasing an additional 122 shares in the last quarter. Finally, Brookstone Capital Management lifted its holdings in Zimmer Biomet by 1.3% in the 3rd quarter. Brookstone Capital Management now owns 9,350 shares of the medical equipment provider’s stock worth $921,000 after purchasing an additional 123 shares in the last quarter. Hedge funds and other institutional investors own 88.89% of the company’s stock.

Zimmer Biomet Price Performance

ZBH stock opened at $98.74 on Monday. Zimmer Biomet Holdings, Inc. has a 52 week low of $84.59 and a 52 week high of $114.44. The firm has a market capitalization of $19.57 billion, a P/E ratio of 27.89, a price-to-earnings-growth ratio of 2.02 and a beta of 0.62. The company has a fifty day simple moving average of $90.64 and a two-hundred day simple moving average of $95.88. The company has a quick ratio of 1.10, a current ratio of 1.98 and a debt-to-equity ratio of 0.55.

Zimmer Biomet (NYSE:ZBH) last posted its earnings results on Tuesday, February 10th. The medical equipment provider reported $2.42 earnings per share for the quarter, topping analysts’ consensus estimates of $2.38 by $0.04. The firm had revenue of $2.24 billion for the quarter, compared to the consensus estimate of $2.22 billion. Zimmer Biomet had a net margin of 8.56% and a return on equity of 12.93%. During the same period in the previous year, the firm posted $2.31 EPS. The business’s quarterly revenue was up 10.9% on a year-over-year basis. Zimmer Biomet has set its FY 2026 guidance at 8.300-8.450 EPS. Analysts anticipate that Zimmer Biomet Holdings, Inc. will post 8.22 earnings per share for the current fiscal year.

Zimmer Biomet Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Friday, January 30th. Shareholders of record on Tuesday, December 30th were given a dividend of $0.24 per share. The ex-dividend date was Tuesday, December 30th. This represents a $0.96 dividend on an annualized basis and a yield of 1.0%. Zimmer Biomet’s dividend payout ratio is 27.12%.

Wall Street Analyst Weigh In

ZBH has been the topic of several recent analyst reports. Johnson Rice set a $112.00 price objective on shares of Zimmer Biomet in a research report on Wednesday, November 5th. TD Cowen raised shares of Zimmer Biomet from a “hold” rating to a “buy” rating in a research note on Monday, January 26th. Royal Bank Of Canada reduced their price target on shares of Zimmer Biomet from $111.00 to $101.00 and set an “outperform” rating on the stock in a report on Thursday, November 6th. Weiss Ratings reissued a “hold (c-)” rating on shares of Zimmer Biomet in a report on Wednesday, January 21st. Finally, William Blair assumed coverage on Zimmer Biomet in a report on Friday. They issued a “market perform” rating on the stock. One analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, ten have issued a Hold rating and three have assigned a Sell rating to the stock. Based on data from MarketBeat.com, Zimmer Biomet has an average rating of “Hold” and an average target price of $106.20.

Zimmer Biomet Profile

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.